A Comparative Study of Novel Fibrosis Index and Other Non-invasive Serum Indices for Predicting Fibrosis in Patients of Chronic Liver Disease.

Autor:	Singh K; Internal Medicine, King George's Medical University, Lucknow, IND., Lamba M; Internal Medicine, King George's Medical University, Lucknow, IND., Kumar V; Internal Medicine, King George's Medical University, Lucknow, IND., Ahuja P; Internal Medicine, King George's Medical University, Lucknow, IND., Gupta KK; Internal Medicine, King George's Medical University, Lucknow, IND., Reddy H; Internal Medicine, King George's Medical University, Lucknow, IND., Patwa A; Internal Medicine, King George's Medical University, Lucknow, IND., Rungta S; Gastroenterology, King George's Medical University, Lucknow, IND., Verma S; Internal Medicine, King George's Medical University, Lucknow, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jul 02; Vol. 16 (7), pp. e63658. Date of Electronic Publication: 2024 Jul 02 (Print Publication: 2024).
DOI:	10.7759/cureus.63658
Abstrakt:	Introduction Chronic liver disease progression leads to liver fibrosis/cirrhosis. Transient Elastography is used for staging liver fibrosis but ascites, obesity, and operator experience limit its applicability. In this study, we compared various non-invasive serum indices in predicting fibrosis in chronic liver disease patients. Materials and methods A total of 142 cases of confirmed Chronic Liver Disease were included. Quantitative determination of liver stiffness by Transient Elastography and relevant blood investigations was done. We compared the liver stiffness measurement by Transient Elastography and fibrosis indices, i.e., Aspartate Transaminase (AST) to Alanine Transaminase (ALT) Ratio (AAR), AST to Platelet Ratio Index (APRI), Fibrosis Index (FI), Fibrosis-4 (FIB-4) Index, Age-Platelet Index (API), Pohl score, and Fibrosis Cirrhosis Index (FCI) with Novel Fibrosis Index (NFI), to predict liver fibrosis stages. Results The optimum cutoff of NFI for the F4 stage was ≥ 6670 with a sensitivity of 75.8% and specificity of 81.8%, for the F3 stage was ≥ 2112 with a sensitivity of 63.6% and specificity of 72.7%, and for the F2 stage was ≥ 1334 with a sensitivity of 100% and specificity of 56.3%. The NFI had the maximum area under the curve compared to other indices in predicting fibrosis stages. Conclusion The Novel Fibrosis Index was the best in predicting fibrosis stages in Chronic Liver Disease patients, with good performance in predicting the F4 stage. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, King George’s Medical University, Lucknow issued approval 103rd ECM II B-Thesis/P21. The Institutional Ethics Committee in its meeting held on 19th February 2021 has reviewed and discussed your clarification via letter no. 319/MED/2021 dated 12th February 2021 to conduct the research proposal entitled "A Comparative Study Of Novel Fibrosis Index And Other Non-Invasive Serum Indices For Predicting Fibrosis in Patients of Chronic Liver Disease" submitted by you. EC Decision: Approved. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Singh et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu